{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T14:38:49Z","timestamp":1723127929900},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T00:00:00Z","timestamp":1559779200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T00:00:00Z","timestamp":1559779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s00702-019-02023-x","type":"journal-article","created":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T04:42:17Z","timestamp":1559796137000},"page":"1047-1050","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Do complexing proteins provide mechanical protection for botulinum neurotoxins?"],"prefix":"10.1007","volume":"126","author":[{"given":"Dirk","family":"Dressler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizhen","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fereshte","family":"Adib Saberi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Bigalke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,6]]},"reference":[{"issue":"Suppl 4","key":"2023_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1468-1331.2006.01649.x","volume":"13","author":"KR Aoki","year":"2006","unstructured":"Aoki KR, Ranoux D, Wissel J (2006) Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur J Neurol 13(Suppl 4):10\u201319","journal-title":"Eur J Neurol"},{"key":"2023_CR2","first-page":"38","volume":"1","author":"F Buelbring","year":"1946","unstructured":"Buelbring F (1946) Observations on the isolated phrenic nerve diaphragm preparation in the rat. Br J Pharmacol 1:38\u201361","journal-title":"Br J Pharmacol"},{"key":"2023_CR3","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1128\/IAI.66.6.2420-2425.1998","volume":"66","author":"F Chen","year":"1998","unstructured":"Chen F, Kuziemko GM, Stevens RC (1998) Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex species. Infect Immun 66:2420\u20132425","journal-title":"Infect Immun"},{"issue":"Suppl 1","key":"2023_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/17429590701523794","volume":"9","author":"AT De Almeida","year":"2007","unstructured":"De Almeida AT, de Boulle K (2007) Diffusion characteristics of botulinum neurotoxin products and their clinical significance in cosmetic applications. J Cosmet Laser Ther 9(Suppl 1):17\u201322","journal-title":"J Cosmet Laser Ther"},{"key":"2023_CR5","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00702-016-1538-1","volume":"123","author":"D Dressler","year":"2016","unstructured":"Dressler D, Bigalke H (2016) Reconstituting botulinum toxin drugs: shaking, stirring or what? J Neural Transm 123:523\u2013525","journal-title":"J Neural Transm"},{"key":"2023_CR6","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s00702-017-1767-y","volume":"124","author":"D Dressler","year":"2017","unstructured":"Dressler D, Bigalke H (2017) Long-term stability of reconstituted incobotulinumtoxinA: how can we reduce costs of botulinum toxin therapy? J Neural Transm 124:1223\u20131225","journal-title":"J Neural Transm"},{"key":"2023_CR7","doi-asserted-by":"crossref","unstructured":"Dressler D, Foster K (2018) Pharmacology of Botulinum Toxins. In: Dressler D, Altenm\u00fcller E, Krauss JK (Eds) Treatment of Dystonia. Cambridge University Press, Cambridge.","DOI":"10.1017\/9781316459324"},{"key":"2023_CR8","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.toxicon.2010.12.019","volume":"57","author":"KH Eisele","year":"2011","unstructured":"Eisele KH, Fink K, Vey M, Taylor HV (2011) Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon 57:555\u2013565","journal-title":"Toxicon"},{"key":"2023_CR9","first-page":"325","volume":"4","author":"J Frevert","year":"2010","unstructured":"Frevert J, Dressler D (2010) Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics 4:325\u2013332","journal-title":"Biologics"},{"key":"2023_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/jb\/mvj161","volume":"140","author":"Y Fujinaga","year":"2006","unstructured":"Fujinaga Y (2006) Transport of bacterial toxins into target cells: pathways followed by cholera toxin and botulinum progenitor toxin. J Biochem. 140:155\u2013160","journal-title":"J Biochem."},{"key":"2023_CR11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1006\/exnr.1997.6580","volume":"147","author":"H Goschel","year":"1997","unstructured":"Goschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H (1997) Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies: therapeutic consequences. Exp Neurol 147:96\u2013102","journal-title":"Exp Neurol"},{"key":"2023_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1099\/mic.0.021246-0","volume":"155","author":"Y Jin","year":"2009","unstructured":"Jin Y, Takegahara Y, Sugawara Y, Matsumura T, Fujinaga Y (2009) Disruption of the epithelial barrier by botulinum haemagglutinin (HA) proteins\u2013differences in cell tropism and the mechanism of action between HA proteins of types A or B, and HA proteins of type C. Microbiology 155:35\u201345","journal-title":"Microbiology"},{"key":"2023_CR13","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1016\/S0041-0101(01)00157-X","volume":"39","author":"EA Johnson","year":"2001","unstructured":"Johnson EA, Bradshaw M (2001) Clostridium\n                           botulinum and its neurotoxins: a metabolic and cellular perspective. Toxicon 39:1703\u20131722","journal-title":"Toxicon"},{"key":"2023_CR14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1128\/IAI.16.1.107-109.1977","volume":"16","author":"I Ohishi","year":"1977","unstructured":"Ohishi I, Sugii S, Sakaguchi G (1977) Oral toxicities of Clostridium botulinum toxins in response to molecular size. Infect Immun 16:107\u2013109","journal-title":"Infect Immun"},{"key":"2023_CR15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/14764170802094282","volume":"10","author":"A Pickett","year":"2008","unstructured":"Pickett A, Dodd S, Rzany B (2008) Confusion about diffusion and the art of misinterpreting data when comparing different botulinum toxins used in aesthetic applications. J Cosmet Laser Ther 10:181\u2013183","journal-title":"J Cosmet Laser Ther"},{"key":"2023_CR16","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nrmicro3295","volume":"12","author":"O Rossetto","year":"2014","unstructured":"Rossetto O, Pirazzini M, Montecucco C (2014) Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol 12:535\u2013549","journal-title":"Nat Rev Microbiol"},{"issue":"Suppl 4","key":"2023_CR17","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1111\/j.1524-4725.2010.01702.x","volume":"36","author":"D Shome","year":"2010","unstructured":"Shome D, Nair AG, Kapoor R, Jain V (2010) Botulinum toxin A: is it really that fragile a molecule? Dermatol Surg 36(Suppl 4):2106\u20132110","journal-title":"Dermatol Surg"},{"key":"2023_CR18","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0041-0101(03)00196-X","volume":"42","author":"DD Tang-Liu","year":"2003","unstructured":"Tang-Liu DD, Aoki KR, Dolly JO, de Paiva A, Houchen TL, Chasseaud LF, Webber C (2003) Intramuscular injection of 125I-botulinum neurotoxin-complex versus 125I-botulinum-free neurotoxin: time course of tissue distribution. Toxicon 42:461\u2013469","journal-title":"Toxicon"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-019-02023-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-019-02023-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-019-02023-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T23:24:02Z","timestamp":1591313042000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-019-02023-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,6]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["2023"],"URL":"https:\/\/doi.org\/10.1007\/s00702-019-02023-x","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,6]]},"assertion":[{"value":"1 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"DD received honoraria for services provided to Allergan, Ipsen, Merz, Lanzhou Institute of Biological Products, Medy-Tox, Revance, Desitin, Syntaxin, Abbvie, Medtronic, St Jude, Boston Scientific, Almirall, Bayer, Sun, Teva, UCB, IAB-Interdisciplinary Working Group for Movement Disorders. He is a shareholder of Allergan and holds patents on botulinum toxin and botulinum toxin therapy. LP has nothing to declare. FAS received honoraria for services provided to Abbvie, Almirall, Allergan, Asklepios, Bayer, Desitin, Dynamed, Hempel GesundheitsPartner, Ipsen, Johnson & Johnson, Licher, Meda, Medtronic, Medizinische Hochschule Hannover, Merz, Orion, ParkinsonNet, PTZ Nawrath, Sensomotorik & Rehabilitation Hellmuth & Thiel, Sintetica, Sporlastic, Sun, Teva, Tricumed, TRS Med and UCB. HB has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}